| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | -499.7MM | -380% |
| Operating Income | -69MM | +7% |
| Operating Expenses | -518.6MM | -313% |
| Net Income | 55.9MM | -166% |
| R&D | 19.4MM | -0% |
| G&A | 72.9MM | +1% |
| Amortization | 21.5MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
The acquired assets generate about $100 million in annual revenue, according to the deal announcement.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with En
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency v
Investors in OPKO Health, Inc. ( NASDAQ:OPK ) had a good week, as its shares rose 3.1% to close at US$1.00 following...
OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript February 27, 2024 OPKO Health, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
OPKO Health ( NASDAQ:OPK ) Full Year 2023 Results Key Financial Results Revenue: US$863.5m (down 14% from FY 2022). Net...